Assertio Therapeutics, Inc. [ASRT] saw a change by -8.78% with the Thursday trading session, closing the trade at the price of $1.20. The company is holding 82.52M shares with keeping 79.49M floating shares. With the latest trading session, the stock is set at 74.99% off compared to its 52-week low, sliding -79.25% from high for the same period of time.

Since its 90-day high, the share price saw a move by -30.12%, trading +74.99% in oppose to its 90-day low While during the day, 82.52M shares valued at 815416 were bought and sold.

Assertio Therapeutics, Inc. [NASDAQ:ASRT]: Analyst Rating and Earnings

Its stock price has been found in the range of 0.68 to 5.76. This is compared to its latest closing price of $1.31.

Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for 03/03/2020.

Fundamental Analysis of Assertio Therapeutics, Inc. [ASRT]

Now let’s turn to look at profitability: with a current Operating Margin for Assertio Therapeutics, Inc. [ASRT] sitting at +20.45 and its Gross Margin at +61.43, this company’s Net Margin is now -22.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is 8.06, and its Return on Invested Capital has reached 13.30%. Its Return on Equity is 18.93, and its Return on Assets is 3.74. These metrics suggest that this Assertio Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Assertio Therapeutics, Inc. [ASRT] has generated a Total Debt to Total Equity ratio of 256.93. Similarly, its Total Debt to Total Capital is 71.98, while its Total Debt to Total Assets stands at 60.68. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 0.93, and its Long-Term Debt to Total Capital is 202.47.

What about valuation? This company’s Enterprise Value to EBITDA is 3.18 and its Total Debt to EBITDA Value is 3.33. The Enterprise Value to Sales for this firm is now 2.54, and its Total Debt to Enterprise Value stands at 0.82. Assertio Therapeutics, Inc. [ASRT] has a Price to Book Ratio of 1.05, a Price to Cash Flow Ratio of 3.20.

Shifting the focus to workforce efficiency, Assertio Therapeutics, Inc. [ASRT] earns $2,687,672 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.68 and its Total Asset Turnover is 0.32. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.83 and its Current Ratio is 0.85. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.

Assertio Therapeutics, Inc. [ASRT] has 82.52M shares outstanding, amounting to a total market cap of $108.10M. Its stock price has been found in the range of 0.68 to 5.76. At its current price, it has moved down by -79.25% from its 52-week high, and it has moved up 74.99% from its 52-week low.

This stock’s Beta value is currently 2.18, which indicates that it is 7.34% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 47.64. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Assertio Therapeutics, Inc. [ASRT] a Reliable Buy?

Assertio Therapeutics, Inc. [ASRT] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.